Vaccine Therapy in Preventing Human Papillomavirus Infection in Young HIV-Positive Male Patients Who Have Sex With Males

Completed · Phase 2

Conditions studied: Anal Cancer, Nonneoplastic Condition, Penile Cancer, Precancerous Condition

In brief

RATIONALE: Vaccines made from a gene-modified virus may help the body build an effective immune response to prevent viral infection. PURPOSE: This phase II trial is studying how well vaccine therapy works in preventing human papillomavirus (HPV) infection in young HIV-positive male patients who have sex with males.

Key facts

Study ID
NCT01209325
Run by
AIDS Malignancy Consortium
People needed
149
Starts
2011-06-28
Expected to finish
2017-12-12
Last updated by the study team
2020-08-11

Who can join

Age: 13 and older, up to 26. Sex: male. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.